ClinicalTrials.gg
RecruitingNCT05674656Updated Sep 19, 2024

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

A Phase 1/2 interventional study of Dolutegravir/Rilpivirine FDC in HIV Infections, sponsored by ViiV Healthcare. Recruiting at 8 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Planned enrollment
49th of 55
20 · median 126
Started
2023
with 4 others
Phase 1/2
3 of 55
2 open now
Registered
44th of 55
by date
Lead sponsor
26 of 55
ViiV Healthcare

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 49th largest by planned enrollment, is one of 5 that started in 2023, is one of 3 in phase 1/2, and was the 44th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA [Ribonucleic Acid] \< 50 [cells per milliliter] c/mL) children 6 to less than 12 years of age, weighing at least 25 kilogram (kg).

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Dolutegravir
  • Rilpivirine
  • JULUCA
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Human immuno virus Type-1 (-1) infected child 6 years to less than 12 years of age at the time of signing the form .
  • Body weight greater than or equal to 25 kilogram (kg) at entry.
  • Confirmed HIV-1-infection
  • Participant has taken the same Antiretroviral therapy (ART) regimen in the 6 months (180 days) prior to Screening, as determined by the site investigator based on participant/parent/guardian report and available medical records.
  • Has a plasma HIV-1 Ribonucleic Acid (RNA) result less than 50 copies/mL at Screening
  • Has at least one documented plasma HIV-1 RNA result less than the lower limit of detection of the assay from a specimen collected in the 6-12 months (180-365 days) prior to Screening OR Has at least one documented plasma HIV-1 RNA result less than the lower limit of detection of the assay from a specimen collected less than 6 months (within 179 days) prior to entry and at least one documented plasma HIV-1 RNA result less than the lower limit of detection of the assay from a specimen collected in the 12-18 months (365-545 days) prior to Screening
  • For participants of (defined as having reached menarche), not pregnant based on testing performed at Screening (i.e., from a specimen collected within 30 days prior to entry) and at Baseline/Day 1.
  • For participants of reproductive potential who are engaging in sexual activity that could lead to pregnancy, willing to use two methods of while receiving study drug and for approximately one month after permanently discontinuing study drug, based on participant/parent/guardian report at entry.
  • For participants of reproductive potential, not breastfeeding based on participant/parent/ guardian report at Baseline/Day 1.

Exclusion criteria

Exclusion Criteria:

  • Documented resistance (ever) to Non-nucleoside reverse transcriptase inhibitors (NNRTIs) or integrase inhibitors
  • Documented -1 RNA result greater than or equal to the lower limit of detection of the assay based on a specimen collected in the 12 months (365 days) prior to Screening
  • Any change (ever) of any Antiretroviral (ARV) agent due to virologic failure, as determined by the site investigator based on participant/parent/guardian report and available medical records
  • Has a history (ever) of allergy to DTG, RPV, or any other component of JULUCA as determined by the site investigator based on participant/parent/guardian report and available medical records.
  • Has a history (ever) of congestive heart failure, symptomatic arrhythmia, or any cardiac disease as determined by the site investigator based on participant/ parent/guardian report and available medical records
  • Has a history (ever) of unstable liver disease (defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, or known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) as determined by the site investigator based on participant/parent/guardian report and available medical records
  • Has any of the following as determined by the site investigator based on participant/ parent/guardian report and available medical records: Current clinical evidence of pancreatitis; Currently active AIDS-defining (WHO Clinical Stage 4) opportunistic infection; Currently active TB and/or current rifamycin-containing TB treatment.
  • Has an anticipated need for any therapy during the first 24 weeks of study and for HCV therapy based on interferon or any drugs that have a potential for adverse drug: drug interactions with study treatment throughout the entire study period.
  • Receipt of the following as determined by the site investigator based on participant/ parent/guardian report and available medical records: Any agent within 90 days prior to entry; Any prohibited medication within 30 days prior to entry; Any medication with a known risk of Torsades de Pointes within seven days prior to entry
  • Receipt (ever) of an ART regimen that included both DTG and RPV, as determined by the site investigator based on participant/parent/guardian report and available medical records
  • Any ≥ grade 3 result for the following based on grading per the Division of Acquired Immunodeficiency Syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events: (\<8.5 gram per deciliter [g/dL] or \<5.25 millimoles per liter [mmol/L]); (\<600 cells/mm\^3 or \<0.600 x 109 cells/L); count (\<50,000cells/mm\^3 or \<50.00 x 109 cells/L); Estimated (eGFR: \<60ml/min/1.73m\^2); (≥5.0 x [ULN]); Aspartate Aminotransferase (AST) (≥5.0 x ULN)
  • Has the following combination of laboratory test results at screening: Alanine transaminase [ALT] greater than or equal to 3 x ULN and total greater than or equal to 1.5 x ULN and direct bilirubin greater than 35% of total bilirubin
  • Evidence of virus (HBV) infection based on the results of testing at Screening.
  • >450 milliseconds (msec) at Screening
  • Severe acute malnutrition ( [BMI] for age \<-3 or nutritional oedema)
  • Has any documented or suspected clinically significant medical or psychiatric condition or any other condition that, in the opinion of the site investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives.
  • The child is a ward of State or government.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Dolutegravir(DTG)/Rilpivirine (RPV)

    Drug: Dolutegravir/Rilpivirine FDC

Interventions

  • DrugDolutegravir/Rilpivirine FDC

    Drug pages: Dolutegravir · Rilpivirine

    Dolutegravir/Rilpivirine will be administered.

    Also known as: JULUCA

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC0-24h) of DTG

    Time frame: Up to Week 24

  2. Area under the curve (AUC0-24h) of RPV

    Time frame: Up to Week 24

  3. Number of Participants with Adverse Events (AEs) at Week 24

    Time frame: At Week 24

  4. Number of Participants with Grade 3 or higher AEs at Week 24

    Time frame: At Week 24

  5. Number of Participants with Grade 3 or higher AEs assessed as related to study drug at Week 24

    Time frame: At Week 24

  6. Number of Participants with Fatal AEs assessed as related to study drug at Week 24

    Time frame: At Week 24

  7. Number of Participants with Serious Adverse Events (SAEs) assessed as related to study drug at Week 24

    Time frame: At Week 24

  8. Number of Participants with AEs assessed as related to study drug that led to permanent discontinuation of study drug at Week 24

    Time frame: At Week 24

Secondary outcomes

  1. Proportion of Participants with HIV-1 RNA less than 50 copies per milliliter (c/mL)

    Time frame: At Week 24 and 48

  2. Cluster of differentiation 4 (CD4+) Cell Count

    Time frame: At Week 24 and 48

  3. Percentage of CD4+ Cell Count

    Time frame: At Week 24 and 48

  4. Number of Participants with Adverse Events (AEs) at Week 48

    Time frame: At Week 48

  5. Number of Participants with Grade 3 or higher AEs at Week 48

    Time frame: At Week 48

  6. Number of Participants with Grade 3 or higher AEs assessed as related to study drug at Week 48

    Time frame: At Week 48

  7. Number of Participants with Fatal AEs assessed as related to study drug at Week 48

    Time frame: At Week 48

  8. Number of Participants with Serious Adverse Events (SAEs) assessed as related to study drug at Week 48

    Time frame: At Week 48

  9. Number of Participants with AEs assessed as related to study drug that led to permanent discontinuation of study drug at Week 48

    Time frame: At Week 48

  10. Minimum drug concentration (Cmin) of DTG

    Time frame: Up to Week 24

  11. Cmin of RPV

    Time frame: Up to Week 24

  12. Cmin of DTG at Week 4 Visit

    Time frame: Pre-dose, 1, 2, 4, 5, 6, 10 and 24 hours (h) post-dose at Week 4

  13. Cmin of RPV at Week 4 Visit

    Time frame: Pre-dose, 1, 2, 4, 5, 6, 10 and 24 hours (h) post-dose at Week 4

  14. Concentration of HIV-1 RNA

    Time frame: Baseline (Day 1), Week 4, 8, 12, 16, 20, 24, 36 and 48

  15. Number of Participants with HIV-1 Genotype at the time of Virologic failure (HIV-1 RNA greater than or equal to 200 copies/mL)

    Time frame: Baseline (Day 1) and up to Week 48

  16. Number of Participants with HIV-1 Phenotype at the time of Virologic failure (HIV-1 RNA greater than or equal to 200 copies/mL)

    Time frame: Up to Week 48

  17. Number of Participants with HIV-1 genotypes at Baseline, Week 24 and 48

    Time frame: Baseline (Day 1), Week 24 and 48

  18. Number of Participants with Acceptability to JULUCA

    Time frame: At Week 4, 24 and 48

  19. Number of Participants with Adherence to JULUCA

    Time frame: At Week 4, 24 and 48

07

Study locations

7 of 8 sites recruiting
  • GSK Investigational Site
    Long Beach, California 90806, United States
    Recruiting
  • GSK Investigational Site
    Washington, District of Columbia 20010, United States
    Recruiting
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
    Completed

    Not enrolling at this site.

  • GSK Investigational Site
    Miami, Florida 33136, United States
    Recruiting
  • GSK Investigational Site
    Tampa, Florida 33606, United States
    Recruiting
  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77030, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77030, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jun 2026, 34 months after the start.

Of 42 phase 1/2 interventional studies under HIV Infections, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 73. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2022
First posted
Jan 6, 2023
StartActual
Jul 6, 2023
Primary completionEst.
Jun 1, 2026
CompletionEst.
May 3, 2028
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05674656
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jan 6, 2023
Start date
Jul 6, 2023
Primary completion
Jun 1, 2026 (estimated)
Completion
May 3, 2028 (estimated)
Last update
Sep 19, 2024

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dolutegravir · Rilpivirine

Start the discussion